U.S. Markets open in 1 hr 27 mins

Celgene Is Not a Sell, Jim Cramer Rebuts Analysts' Call

Bret Kenwell

Morgan Stanley analysts downgraded shares of Celgene over concerns of generic drug pressures. Those concerns are not warranted just yet and Celgene is not a sell, Jim Cramer reasoned.